BioCentury | Apr 8, 2021
Deals

Rounding up intranasal COVID-19 vaccines: Data Byte

...of India Pvt. Ltd. Altimmune Inc. Codagenix Inc. Coalition for Epidemic Preparedness Innovations (CEPI) University of Hong Kong Meissa Vaccines Inc. eTheRNA immunotherapies N.V. EpiVax...
BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

...Phase Ib/IIa testing for advanced hepatocellular carcinoma.ConserV, eTheRNA in mRNA vaccine dealConserV Bioscience Ltd. partnered with eTheRNA immunotherapies N.V....
...2 Jeff Cranmer Amunix Pharmaceuticals Inc. Atai Life Sciences AG OnKure Inc. Exscientia Ltd. Geneos Therapeutics Inc. Takeda Pharmaceutical Co. Ltd. ConserV Bioscience Ltd. eTheRNA immunotherapies N.V. Blue...
BioCentury | Jun 16, 2020
Finance

eTheRNA’s €34M series B to support different take on COVID-19 vaccine, build out core cancer pipeline

...The series B round for eTheRNA will fund the Belgian company’s core immuno-oncology pipeline as well...
...immuno-oncology pipeline as well as its different mRNA approach to combat the threat of coronaviruses. eTheRNA immunotherapies N.V....
...target the SARS-CoV-2 spike protein, which has regions that differ from other coronavirus spikes, whereas eTheRNA...
BioCentury | May 21, 2020
Product Development

Translate Bio brings chronic disease-scale manufacturing to COVID-19 mRNA vaccine

...companies that have disclosed preclinical mRNA vaccine programs for COVID-19 include Capricor Therapeutics Inc. (NASDAQ:CAPR), eTheRNA immunotherapies N.V....
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

...and cancer company Galecto Biotech AB hired Bertil Lindmark as CMO. He was CMO of eTheRNA...
BioCentury | Jan 6, 2020
Company News

Bancel letter showcases Moderna’s focus on mRNA vaccines

...to antigen presenting cells (see “The Quiet Disrupters” and “Amplifying Oligos” ). CureVac AG and eTheRNA immunotherapies N.V....
BioCentury | May 29, 2019
Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

...of Vivus Inc. (NASDAQ:VVUS) and was CFO of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX). mRNA immunotherapy company eTheRNA immunotherapies N.V....
...June 3. Sandi Wong and Chris Lieu, Staff Writers Alnylam Pharmaceuticals Inc. ArcherDx Inc. Audentes Therapeutics Inc. Black Diamond Therapeutics Inc. eTheRNA immunotherapies N.V. HeartFlow...
BioCentury | Dec 8, 2018
Finance

Moderna’s land grab

...raised at least $404.3 million in venture funding and at least $147.3 million via partnerships. eTheRNA immunotherapies N.V....
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

...of Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX), AM-Pharma B.V. (Bunnik, the Netherlands), Mint Solutions (Amsterdam, the Netherlands), eTheRNA Immunotherapies N.V....
BioCentury | Apr 7, 2017
Finance

Fast-growing evergreen

...S.A. and Novadip Biosciences S.A. , as well as cancer companies iTeos Therapeutics S.A. , eTheRNA immunotherapies N.V....
Items per page:
1 - 10 of 17
BioCentury | Apr 8, 2021
Deals

Rounding up intranasal COVID-19 vaccines: Data Byte

...of India Pvt. Ltd. Altimmune Inc. Codagenix Inc. Coalition for Epidemic Preparedness Innovations (CEPI) University of Hong Kong Meissa Vaccines Inc. eTheRNA immunotherapies N.V. EpiVax...
BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

...Phase Ib/IIa testing for advanced hepatocellular carcinoma.ConserV, eTheRNA in mRNA vaccine dealConserV Bioscience Ltd. partnered with eTheRNA immunotherapies N.V....
...2 Jeff Cranmer Amunix Pharmaceuticals Inc. Atai Life Sciences AG OnKure Inc. Exscientia Ltd. Geneos Therapeutics Inc. Takeda Pharmaceutical Co. Ltd. ConserV Bioscience Ltd. eTheRNA immunotherapies N.V. Blue...
BioCentury | Jun 16, 2020
Finance

eTheRNA’s €34M series B to support different take on COVID-19 vaccine, build out core cancer pipeline

...The series B round for eTheRNA will fund the Belgian company’s core immuno-oncology pipeline as well...
...immuno-oncology pipeline as well as its different mRNA approach to combat the threat of coronaviruses. eTheRNA immunotherapies N.V....
...target the SARS-CoV-2 spike protein, which has regions that differ from other coronavirus spikes, whereas eTheRNA...
BioCentury | May 21, 2020
Product Development

Translate Bio brings chronic disease-scale manufacturing to COVID-19 mRNA vaccine

...companies that have disclosed preclinical mRNA vaccine programs for COVID-19 include Capricor Therapeutics Inc. (NASDAQ:CAPR), eTheRNA immunotherapies N.V....
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

...and cancer company Galecto Biotech AB hired Bertil Lindmark as CMO. He was CMO of eTheRNA...
BioCentury | Jan 6, 2020
Company News

Bancel letter showcases Moderna’s focus on mRNA vaccines

...to antigen presenting cells (see “The Quiet Disrupters” and “Amplifying Oligos” ). CureVac AG and eTheRNA immunotherapies N.V....
BioCentury | May 29, 2019
Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

...of Vivus Inc. (NASDAQ:VVUS) and was CFO of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX). mRNA immunotherapy company eTheRNA immunotherapies N.V....
...June 3. Sandi Wong and Chris Lieu, Staff Writers Alnylam Pharmaceuticals Inc. ArcherDx Inc. Audentes Therapeutics Inc. Black Diamond Therapeutics Inc. eTheRNA immunotherapies N.V. HeartFlow...
BioCentury | Dec 8, 2018
Finance

Moderna’s land grab

...raised at least $404.3 million in venture funding and at least $147.3 million via partnerships. eTheRNA immunotherapies N.V....
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

...of Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX), AM-Pharma B.V. (Bunnik, the Netherlands), Mint Solutions (Amsterdam, the Netherlands), eTheRNA Immunotherapies N.V....
BioCentury | Apr 7, 2017
Finance

Fast-growing evergreen

...S.A. and Novadip Biosciences S.A. , as well as cancer companies iTeos Therapeutics S.A. , eTheRNA immunotherapies N.V....
Items per page:
1 - 10 of 17